We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new report by the Organisation for Economic Co-operation and Development
(OECD) of its member states claims Belgium is the lead performer in terms of
biopharmaceutical innovation.
A former Japanese health minister has reintroduced a series of radical
plans to reform pharmaceutical pricing. Proposed changes to the current system,
which bases pricing on efficacy comparisons, might prove too radical for the
government's tastes; however, the more cautious steps already taken by officials
to reform pricing already suggests that a more cost-conscious approach is gaining
ground.
Anadys Pharmaceuticals, a biopharmaceutical company committed to the discovery,
development and commercialization of novel anti-infective medicines, announced
today the expiration of the waiting period under the Hart-Scott-Rodino (HSR)
Antitrust Improvements Act for the Company's exclusive global license and co-development
agreement with Novartis.
ChemDiv and Euroscreen announced their partnership in the discovery and development
of drug candidates against a panel of chemokine receptors, a specific subset
of G Protein Coupled-Receptor (GPCR) targets involved in inflammation, immunomodulation,
and carcinogenesis.
Consumer products maker Procter & Gamble has signed an agreement with Novartis
AG to market the Swiss drugmaker's Enablex overactive bladder drug in the United
States, Novartis said in a statement on Wednesday.
Drug maker Eli Lilly said Wednesday that it signed a licensing agreement with
Japanese drug maker Taisho Pharmaceutical to eventually market a novel Type
2 diabetes treatment currently in development.
The UAE is to implement new drug price cuts from September. New cost-conscious
legislation approved by the country's health minister will reduce retail profit
margins from 55% to 44%.